CA2778735A1 - Induction de l'arteriogenese - Google Patents

Induction de l'arteriogenese Download PDF

Info

Publication number
CA2778735A1
CA2778735A1 CA2778735A CA2778735A CA2778735A1 CA 2778735 A1 CA2778735 A1 CA 2778735A1 CA 2778735 A CA2778735 A CA 2778735A CA 2778735 A CA2778735 A CA 2778735A CA 2778735 A1 CA2778735 A1 CA 2778735A1
Authority
CA
Canada
Prior art keywords
donor
arterial insufficiency
arterial
administered
insufficiency
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2778735A
Other languages
English (en)
Inventor
Michaels Gorath
Robert Paeschke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
G Pohl Boskamp GmbH and Co KG
Original Assignee
G Pohl Boskamp GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G Pohl Boskamp GmbH and Co KG filed Critical G Pohl Boskamp GmbH and Co KG
Priority to CA2778735A priority Critical patent/CA2778735A1/fr
Publication of CA2778735A1 publication Critical patent/CA2778735A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
CA2778735A 2012-05-31 2012-05-31 Induction de l'arteriogenese Abandoned CA2778735A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2778735A CA2778735A1 (fr) 2012-05-31 2012-05-31 Induction de l'arteriogenese

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2778735A CA2778735A1 (fr) 2012-05-31 2012-05-31 Induction de l'arteriogenese

Publications (1)

Publication Number Publication Date
CA2778735A1 true CA2778735A1 (fr) 2013-11-30

Family

ID=49714071

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2778735A Abandoned CA2778735A1 (fr) 2012-05-31 2012-05-31 Induction de l'arteriogenese

Country Status (1)

Country Link
CA (1) CA2778735A1 (fr)

Similar Documents

Publication Publication Date Title
WO2007029255A1 (fr) Prevention de l'hypotension et stabilisation de la pression sanguine chez des patients hemodialyses
BRPI0518266B1 (pt) medicamento oral de liberação modificada de pelo menos um princípio ativo sob a forma multimicrocapsular
JP2011522876A (ja) 永続性心房細動を予防するためのドロネダロン
RU2627842C2 (ru) Средство для улучшения диастолической функции левого желудочка
JP2007517911A (ja) 心臓血管の適応症および腎臓の適応症に対してｃｇｒｐを使用する方法
US10987332B2 (en) Sprayable aqueous composition comprising glyceryl trinitrate
CN104080451B (zh) 吲哚异羟肟酸和吲哚啉异羟肟酸于治疗心脏衰竭或神经损伤的用途
EP2668947B1 (fr) Induction de l'artériogénèse par un donneur d'oxyde nitrique tel que la nitroglycérine
JP2011511844A (ja) 心血管疾患の処置のためのラノラジンの使用
US20220233501A1 (en) Therapeutic combinations
CA2778735A1 (fr) Induction de l'arteriogenese
US20190365693A1 (en) Induction of arteriogenesis
EP2854794B1 (fr) Granules stabilisées de trinitrate de glycéryl pour induire l'artériogénèse
FR2845916A1 (fr) Composition pharmaceutique associant le tenatoprazole et un antagoniste des recepteurs h2 a l'histamine
US10647745B2 (en) Compound for treating sequelae of ischemic cerebral stroke
Unnisa et al. Study on development and tissue permeation of different formulations of Fasudil.
Nast Clinical findings in the treatment of hypertensive crisis with nitroglycerin
US20200108015A1 (en) Sustained Release Nitric Oxide in Intestinal Tract

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20200831